KẾT QUẢ HÓA XẠ TRỊ ĐỒNG THỜI TRIỆT CĂN UNG THƯ THỰC QUẢN 1/3 GIỮA – DƯỚI BẰNG PHÁC ĐỒ XELOX TẠI BỆNH VIỆN K

Abstract

Objective: The aims of our study were to investigate response rate and related factors of definitive concurrent chemoradiotherapy treatment with XELOX regimen. Patients and Methods: A retrospective analysis was conducted on 52 patients with stage Ib–III esophageal cancer treated with XELOX-based concurrent chemoradiotherapy between 2022 and 2024. Treatment response was assessed according to RECIST version 1.1. Tumor response rate, other related factors were determined. Results: Mean age 65,6 ± 6,9 ;common in male (98.1%). Tumors in the middle third of the esophagus (67.3%), with exophytic morphology 53.8%. Squamous cell carcinoma 98.1% cases. T3 stage 67.3%, and lymph node metastases 71.2% at diagnosis. Schedule completed rate was 94.3%. Treatment was discontinued in two patients due to toxicity and in one due to disease progression. The complete response rate 28.8%, and partial response rate 50%. The median follow-up duration was 22.7 months. The 12-month overall survival rate was 61.5%. Median progression-free survival was 19,6 ± 1.64 months (95% CI: 16,4–22,8). Adverse events were primarily grade 1–2. One case of grade 3 anemia, one case of grade 3 thrombocytopenia, and one case of grade 4 neutropenia were observed. Conclusion: Concurrent chemoradiotherapy with XELOX regimen demonstrated a high overall response rate exceeding 70%, with treatment response significantly associated with disease stage